Literature DB >> 28397112

Cell Therapy for Multiple Sclerosis.

Pamela Sarkar1, Claire M Rice1, Neil J Scolding2.   

Abstract

Cell therapy is considered a promising potential treatment for multiple sclerosis, perhaps particularly for the progressive form of the disease for which there are currently no useful treatments. Over the past two decades or more, much progress has been made in understanding the biology of MS and in the experimental development of cell therapy for this disease. Three quite distinct forms of cell therapy are currently being pursued. The first seeks to use stem cells to replace damaged myelin-forming oligodendrocytes within the CNS; the second aims, in effect, to replace the individual's misfunctioning immune system, making use of haematopoietic stem cells; and the third seeks to utilise endogenous stem cell populations by mobilisation with or without in vitro expansion, exploiting their various reparative and neuroprotective properties. In this article we review progress in these three separate areas, summarising the experimental background and clinical progress thus far made.

Entities:  

Mesh:

Year:  2017        PMID: 28397112     DOI: 10.1007/s40263-017-0429-9

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   6.497


  95 in total

1.  High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.

Authors:  Yury L Shevchenko; Andrei A Novik; Aleksey N Kuznetsov; Boris V Afanasiev; Igor A Lisukov; Vladimir A Kozlov; Oleg A Rykavicin; Tatyana I Ionova; Vladimir Y Melnichenko; Denis A Fedorenko; Alexander D Kulagin; Sergei V Shamanski; Roman A Ivanov; Gary Gorodokin
Journal:  Exp Hematol       Date:  2008-05-12       Impact factor: 3.084

Review 2.  Mesenchymal stem cell transplantation in multiple sclerosis.

Authors:  Jeffrey A Cohen
Journal:  J Neurol Sci       Date:  2013-01-04       Impact factor: 3.181

Review 3.  NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.

Authors:  Maria Pia Sormani; Paolo A Muraro; Riccardo Saccardi; Gianluigi Mancardi
Journal:  Mult Scler       Date:  2016-07-11       Impact factor: 6.312

4.  Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis.

Authors:  Elizabeth Mallam; Kevin Kemp; Alastair Wilkins; Claire Rice; Neil Scolding
Journal:  Mult Scler       Date:  2010-06-11       Impact factor: 6.312

5.  Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.

Authors:  L von Bahr; I Batsis; G Moll; M Hägg; A Szakos; B Sundberg; M Uzunel; O Ringden; K Le Blanc
Journal:  Stem Cells       Date:  2012-07       Impact factor: 6.277

6.  Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.

Authors:  H Openshaw; B T Lund; A Kashyap; R Atkinson; I Sniecinski; L P Weiner; S Forman
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

Review 7.  A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it's time!

Authors:  Christopher Siatskas; Natalie L Payne; Martin A Short; Claude C A Bernard
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

8.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Richard A Nash; James D Bowen; Peter A McSweeney; Steven Z Pavletic; Kenneth R Maravilla; Man-soo Park; Jan Storek; Keith M Sullivan; Jinan Al-Omaishi; John R Corboy; John DiPersio; George E Georges; Theodore A Gooley; Leona A Holmberg; C Fred LeMaistre; Kate Ryan; Harry Openshaw; Julie Sunderhaus; Rainer Storb; Joseph Zunt; George H Kraft
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

9.  High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.

Authors:  T Kozák; E Havrdová; J Pit'ha; E Gregora; R Pytlík; J Maaloufová; H Marecková; P Kobylka; S Vodvárková
Journal:  Bone Marrow Transplant       Date:  2000-03       Impact factor: 5.483

10.  Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.

Authors:  J D Bowen; G H Kraft; A Wundes; Q Guan; K R Maravilla; T A Gooley; P A McSweeney; S Z Pavletic; H Openshaw; R Storb; M Wener; B A McLaughlin; G R Henstorf; R A Nash
Journal:  Bone Marrow Transplant       Date:  2011-11-07       Impact factor: 5.483

View more
  5 in total

1.  Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation.

Authors:  Mohsen Abbasi-Kangevari; Seyyed-Hadi Ghamari; Fahimeh Safaeinejad; Soheyl Bahrami; Hassan Niknejad
Journal:  Front Immunol       Date:  2019-02-20       Impact factor: 7.561

2.  Efficacy and Safety of Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Multiple Sclerosis, and Ankylosing Spondylitis): A Systematic Review and Meta-Analysis of Randomized Controlled Trial.

Authors:  Liuting Zeng; Ganpeng Yu; Kailin Yang; Wang Xiang; Jun Li; Hua Chen
Journal:  Stem Cells Int       Date:  2022-03-24       Impact factor: 5.443

Review 3.  Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders.

Authors:  Caterina Allegretta; Emanuele D'Amico; Virginia Manuti; Carlo Avolio; Massimo Conese
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 4.  A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells.

Authors:  Geeta Shroff
Journal:  Stem Cells Cloning       Date:  2018-02-12

5.  iTRAQ-based proteomics profiling of Schwann cells before and after peripheral nerve injury.

Authors:  Gui-Dong Shi; Xin Cheng; Xian-Hu Zhou; Bao-You Fan; Yi-Ming Ren; Wei Lin; Xiao-Lei Zhang; Shen Liu; Yan Hao; Zhi-Jian Wei; Shi-Qing Feng
Journal:  Iran J Basic Med Sci       Date:  2018-08       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.